The tumor suppressor p15Ink4b regulates the differentiation and maturation of conventional dendritic cells

Blood

Volumn 119, Issue 21, 2012, Pages 5005-5015

  Fares, Joanna ^a,b   Koller, Richard ^a   Humeniuk, Rita ^a   Wolff, Linda ^a   Bies, Juraj ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR PU 1;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; DENDRITIC CELL; ENZYME PHOSPHORYLATION; EX VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 84861503438     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-387613     Document Type: Article

References (50)

1. Herman JG, Jen J, Merlo A, Baylin SB. Hypermethylation- associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 1996;56(4):722-727.
2. Cameron EE, Baylin SB, Herman JG. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood. 1999;94(7):2445-2451. (Pubitemid 29467693)
3. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91(8):2985-2990. (Pubitemid 28227550)
4. Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood. 1997;90(4):1403-1409. (Pubitemid 27355412)
5. Bies J, Sramko M, Fares J, et al. Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood. 2010;116(6):979-987.
6. Ortega S, Malumbres M, Barbacid M. Cyclin Ddependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002;1602(1):73-87. (Pubitemid 34311901)
7. Schmidt M, Bies J, Tamura T, Ozato K, Wolff L. The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood. 2004;103(11):4142-4149. (Pubitemid 38685355)
8. Rosu-Myles M, Taylor BJ, Wolff L. Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol. 2007;35(3):394-406.
9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673): 245-252. (Pubitemid 28155090)
10. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711. (Pubitemid 37174545)
11. Merad M, Manz MG. Dendritic cell homeostasis. Blood. 2009;113(15):3418- 3427.
12. Naik SH, Sathe P, Park HY, et al. Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol. 2007;8(11):1217-1226. (Pubitemid 350011760)
13. Onai N, Obata-Onai A, Schmid MA, Ohteki T, Jarrossay D, Manz MG. Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol. 2007;8(11): 1207-1216. (Pubitemid 350011759)
14. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 1996;170(1):101-110.
15. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 2000;6(5):1755- 1766.
16. Latres E, Malumbres M, Sotillo R, et al. Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 2000;19(13):3496-3506. (Pubitemid 30428227)
17. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693-1702.
18. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223(1): 77-92. (Pubitemid 29096240)
19. Liebermann DA, Hoffman-Liebermann B. Protooncogene expression and dissection of the myeloid growth to differentiation developmental cascade. Oncogene. 1989;4(5):583-592. (Pubitemid 19139710)
20. Wells AD, Gudmundsdottir H, Turka LA. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest. 1997;100(12):3173-3183. (Pubitemid 28022856)
21. Livak K, Schmittgen T. Analysis of Relative Gene expression Data using Real Time Quantitative PCR and the 2-deltadeltaCT method. Methods. 2001;25(4):402-408. (Pubitemid 34164012)
22. Kanada S, Nishiyama C, Nakano N, et al. Critical role of transcription factor PU. 1 in the expression of CD80 and CD86 on dendritic cells. Blood. 2011;117(7):2211-2222.
23. Hamdorf M, Berger A, Schule S, Reinhardt J, Flory E. PKCdelta-induced PU. 1 phosphorylation promotes hematopoietic stem cell differentiation to dendritic cells. Stem Cells. 2011;29(2):297- 306.
24. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994;179(4):1109-1118.
25. Onai N, Manz MG, Schmid MA. Isolation of common dendritic cell progenitors (CDP) from mouse bone marrow. Methods Mol Biol. 2010;595:195- 203.
26. Santambrogio L, Sato AK, Carven GJ, Belyanskaya SL, Strominger JL, Stern LJ. Extracellular antigen processing and presentation by immature dendritic cells. Proc Natl Acad Sci U S A. 1999;96(26):15056-15061. (Pubitemid 30019764)
27. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci U S A. 1999;96(26):15050- 15055.
28. Haugwitz M, Nourzaie O, Gandlur S, Sagawa H. ProteoTuner: a novel system with rapid kinetics enables reversible control of protein levels in cells and organisms. BioTechniques. 2008;44(3):432- 433.
29. Saxena RK, Vallyathan V, Lewis DM. Evidence for lipopolysaccharide- induced differentiation of RAW264.7 murine macrophage cell line into dendritic like cells. J Biosci. 2003;28(1):129-134. (Pubitemid 36268258)
30. Lee YN, Lee HY, Kang HK, Kwak JY, Bae YS. Phosphatidic acid positively regulates LPSinduced differentiation of RAW264.7 murine macrophage cell line into dendritic-like cells. Biochem Biophys Res Commun. 2004;318(4):839-845.
31. Burkly L, Hession C, Ogata L, et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature. 1995; 373(6514):531-536.
32. Wu L, D'Amico A, Winkel KD, Suter M, Lo D, Shortman K. RelB is essential for the development of myeloid-related CD8alpha-dendritic cells but not of lymphoid-related CD8alpha- dendritic cells. Immunity. 1998;9(6):839-847. (Pubitemid 29024463)
33. Anderson KL, Perkin H, Surh CD, Venturini S, Maki RA, Torbett BE. Transcription factor PU.1 is necessary for development of thymic and myeloid progenitor-derived dendritic cells. J Immunol. 2000;164(4):1855-1861. (Pubitemid 30108739)
34. Guerriero A, Langmuir PB, Spain LM, Scott EW. PU.1 is required for myeloid-derived but not lymphoid- derived dendritic cells. Blood. 2000;95(3): 879-885. (Pubitemid 30062709)
35. Carotta S, Dakic A, D'Amico A, et al. The transcription factor PU. 1 controls dendritic cell development and Flt3 cytokine receptor expression in a dose-dependent manner. Immunity. 2010;32(5): 628-641.
36. Felker P, Sere K, Lin Q, et al. TGF-beta1 accelerates dendritic cell differentiation from common dendritic cell progenitors and directs subset specification toward conventional dendritic cells. J Immunol. 2010;185(9):5326-5335.
37. Hannon GJ, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature. 1994;371(6494):257-261.
38. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991; 9:271-296.
39. Austyn JM. Antigen uptake and presentation by dendritic leukocytes. Semin Immunol. 1992;4(4): 227-236.
40. Inaba K, Steinman RM, Van Voorhis WC, Muramatsu S. Dendritic cells are critical accessory cells for thymus-dependent antibody responses in mouse and in man. Proc Natl Acad Sci U S A. 1983;80(19):6041-6045. (Pubitemid 14228240)
41. Choudhury BA, Liang JC, Thomas EK, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93(3): 780-786. (Pubitemid 29067842)
42. Kharfan-Dabaja M, Ayala E, Lindner I, et al. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol Immunother. 2005;54(1):25-36. (Pubitemid 40064482)
43. Cignetti A, Bryant E, Allione B, Vitale A, Foa R, Cheever MA. CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood. 1999;94(6):2048- 2055.
44. Frikeche J, Clavert A, Delaunay J, et al. Impact of the hypomethylating agent 5-azacytidine on dendritic cells function. Exp Hematol. 2011;39(11): 1056-1063.
45. Paul TA, Bies J, Small D, Wolff L. Signatures of polycomb repression and reduced H3K4 trimethylation are associated with p15INK4b DNA methylation in AML. Blood. 2010;115(15):3098- 3108.
46. Berg T, Guo Y, Abdelkarim M, Fliegauf M, Lubbert M. Reversal of p15/INK4b hypermethylation in AML1/ ETO-positive and -negative myeloid leukemia cell lines. Leuk Res. 2007;31(4):497-506. (Pubitemid 46206089)
47. Dakic A,Wu L, Nutt SL. Is PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis? Trends Immunol. 2007;28(3): 108-114. (Pubitemid 46283693)
48. Fukai T, Nishiyama C, Kanada S, et al. Involvement of PU.1 in the transcriptional regulation of TNF-alpha. Biochem Biophys Res Commun. 2009;388(1):102-106.
49. Nguyen VT, Benveniste EN. Involvement of STAT-1 and ets family members in interferongamma induction of CD40 transcription in microglia/ macrophages. J Biol Chem. 2000;275(31): 23674-23684. (Pubitemid 30624652)
50. Ito T, Nishiyama C, Nakano N, et al. Roles of PU.1 in monocyte- and mast cell-specific gene regulation: PU.1 transactivates CIITA pIV in cooperation with IFN-gamma. Int Immunol. 2009; 21(7):803-816.